Malignant tumors display remarkable heterogeneity to the extent that even at the same tissue site different types of cells with varying genetic background may be found. In contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has been found to be consistently overexpressed by most tumor cells. Scavenger Receptor Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation of cancer cells and thus a potential major impact in carcinogenesis and metastasis. Recent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer. Moreover, genomic data show that depending on the type of cancer, high or low SR-BI expression may promote poor survival. This review discusses the importance of SR-BI as a diagnostic as well as prognostic indicator of cancer to help elucidate the contributions of this protein to cancer development, progression, and survival. In addition, the SR-B1 receptor has been shown to serve as a potential gateway for the delivery of therapeutic agents when reconstituted high density lipoprotein nanoparticles are used for their transport to cancer cells and tumors. Opportunities for the development of new technologies, particularly in the areas of cancer therapy and tumor imaging are discussed.

This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics.

Interleukin-6 (IL-6) is a multifunctional cytokine with a growth promoting role in cancers. In an attempt to evaluate the prognostic significance of IL-6, we have studied the localization of this cytokine by immunohistochemical methods in normal, premalignant, and invasive cervical cancers. We stained frozen sections with a monoclonal antibody specific for human IL-6 and demonstrated that tumor cells show positivity with high intensity and stromal cells with moderate intensity. T cells and macrophages, components of the stroma that secrete IL-6, were also looked at. While T cells showed a weak positive correlation, CD68-positive macrophages showed significant positive correlation (P < 0.05) with IL-6 positivity in stroma. The patients were followed up for 40 months after treatment with standard radiotherapy regimen and showed residual tumor where pretreatment IL-6 levels were high. Our results suggest its possible candidature as a prognostic indicator of cervical cancer.

Progressive accumulation of DNA lesions leads to genetic mutations that are central to the process of tumorigenesis. Human cervix provides an ideal system to determine progressive accumulation of DNA adducts in the target tissue because of its accessibility during routine diagnostic checkups. Uterine cervix samples from various pathologies, i.e. normal (n=13), inflammation (n=9), dysplasia (n=5) and different stages of invasive cancer (n=47), were analyzed for DNA adduct burden by modified 32 P-postlabeling/TLC systems. Six subgroups of adducts were detected in the following descending order of polarities: P-1, P-2, PL-1, PL-2, L-1 and L-2 (P, polar; L, lipophilic; PL, between polar and lipophilic). No qualitative differences were observed in adduct profiles in the various cervix pathologies analyzed. However, significant quantitative differences were found. Previously known lipophilic adducts increased significantly from normal to cancer (144±61 to 503±51 adducts/10 9 nucleotides). Interestingly, the newly discovered polar adducts were present at 61-to 527-fold higher levels than lipophilic adducts. Of all the polar adducts, the known mutagenic lesion, 8-oxodeoxyguanosine, predominated in all cervix conditions. Notably, this lesion was elevated 27-fold in inflammation compared with normal cervix (51,058±9,863 versus 1,886±507 adducts/10 9 nucleotides). The P-1, PL-1, PL-2 and L-1 adducts were elevated 3-to 13-fold in inflammation compared with normal cervix, and were also higher in dysplasia and cancer. Our data suggest that inflam-mation may be involved in directing the course of disease progression by accumulating higher levels of DNA lesions. The data further suggest the biomarker potential of the newly detected array of DNA adducts. Abbreviations: 8-OxodG, 8-oxodeoxyguanosine; CIN, cervical intraepithelial neoplasia; DRZ, diagonal radioactive zone; HPV, human papillomavirus Key words: DNA adducts, oxidative DNA damage, 32 P-postlabeling, cervical cancer, inflammationFigure 3. Scatter plots highlighting the inter-individual variability of different subgroups of adducts in various cervical pathology.

No abstract